{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:01:54Z","timestamp":1780718514203,"version":"3.54.1"},"reference-count":44,"publisher":"The Japanese Society for Medical Mycology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.3314\/mmj.26.008","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T22:12:31Z","timestamp":1780179151000},"page":"117-123","source":"Crossref","is-referenced-by-count":0,"title":["Managing Azole Resistance in <i>Aspergillus<\/i>"],"prefix":"10.3314","volume":"67","author":[{"given":"Hisako","family":"Kushima","sequence":"first","affiliation":[{"name":"Department of Infection Control and Prevention, Fukuoka University Chikushi Hospital"},{"name":"Department of Respiratory Medicine, Fukuoka University Chikushi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukuoka University Chikushi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1842","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Morrissey CO, Kim HY, Duong TN, Moran E, Alastruey-Izquierdo A, Denning DW, et al: Aspergillus fumigatus<\/i>: A systematic review to inform the World Health Organization priority list of fungal pathogens. Med Mycol 62: myad129, 2024.","DOI":"10.1093\/mmy\/myad129"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rath PM, Ansorg R: Value of environmental sampling and molecular typing of aspergilli to assess nosocomial sources of aspergillosis. J Hosp Infect 37: 47–53, 1997.","DOI":"10.1016\/S0195-6701(97)90072-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Dagenais TR, Keller NP: Pathogenesis of Aspergillus fumigatus<\/i> in invasive aspergillosis. Clin Microbiol Rev 22: 447–65, 2009.","DOI":"10.1128\/CMR.00055-08"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Beisswenger C, Hess C, Bals R: Aspergillus fumigatus<\/i> conidia induce interferon-beta signalling in respiratory epithelial cells. Eur Respir J 39: 411–8, 2012.","DOI":"10.1183\/09031936.00096110"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lowes D, Al-Shair K, Newton PJ, Morris J, Harris C, Rautemaa-Richardson R, et al: Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J 49: 1601062, 2017.","DOI":"10.1183\/13993003.01062-2016"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sehgal IS, Dhooria S, Muthu V, Prasad KT, Aggarwal AN, Chakrabarti A, et al: Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: An open-label, randomised controlled trial in India. Lancet Infect Dis 22: 1052–61, 2022.","DOI":"10.1016\/S1473-3099(22)00057-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Takeda K, Suzuki J, Watanabe A, Arai T, Koiwa T, Shinfuku K, et al: High detection rate of azole-resistant Aspergillus fumigatus<\/i> after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance. Med Mycol 59: 327–34, 2021.","DOI":"10.1093\/mmy\/myaa052"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 63: e1–e60, 2016.","DOI":"10.1093\/cid\/ciw326"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al: Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 47: 45–68, 2016.","DOI":"10.1183\/13993003.00583-2015"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kohno S, Izumikawa K: Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus<\/i> infection. Clin Infect Dis 51: 1392–4, 2010.","DOI":"10.1086\/657307"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kohno S, Izumikawa K, Takazono T, Miyazaki T, Yoshida M, Kamei K, et al: Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. J Infect Chemother 29: 163–70, 2023.","DOI":"10.1016\/j.jiac.2022.10.010"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Jean SS, Yang HJ, Hsieh PC, Huang YT, Ko WC, Hsueh PR: In vitro<\/i> susceptibilities of worldwide isolates of intrapulmonary Aspergillus<\/i> species and important Candida<\/i> species in sterile body sites against important antifungals: Data from the antimicrobial testing leadership and surveillance program, 2017–2020. Microbiol Spectr 10: e0296522, 2022.","DOI":"10.1128\/spectrum.02965-22"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ellsworth M, Ostrosky-Zeichner L: Isavuconazole: Mechanism of action, clinical efficacy, and resistance. J Fungi (Basel) 6: 324, 2020.","DOI":"10.3390\/jof6040324"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) J\u00f8rgensen KM, Astvad KMT, Hare RK, Arendrup MC: EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates. Antimicrob Agents Chemother 63: e00073-19, 2019.","DOI":"10.1128\/AAC.00073-19"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Batchelor R, Thomas C, Gardiner BJ, Lee SJ, Fleming S, Wei A, et al: When azoles cannot be used: The clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients. Open Forum Infect Dis 8: ofab113, 2021.","DOI":"10.1093\/ofid\/ofab113"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Toyotome T, Hagiwara D, Kida H, Ogi T, Watanabe A, Wada T, et al: First clinical isolation report of azole-resistant Aspergillus fumigatus<\/i> with TR34<\/sub>\/L98H-type mutation in Japan. J Infect Chemother 23: 579–81, 2017.","DOI":"10.1016\/j.jiac.2016.12.004"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Onishi K, Muhammad Sarumoh B, Hagiwara D, Watanabe A, Kamei K, Toyotome T: Azole-resistant Aspergillus fumigatus<\/i> containing a 34-bp tandem repeat in cyp51A promoter is isolated from the environment in Japan. Med Mycol J 58: E67–E70, 2017.","DOI":"10.3314\/mmj.17-00002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Burks C, Darby A, G\u00f3mez Londo\u00f1o L, Momany M, Brewer MT: Azole-resistant Aspergillus fumigatus<\/i> in the environment: Identifying key reservoirs and hotspots of antifungal resistance. PLoS Pathog 17: e1009711, 2021.","DOI":"10.1371\/journal.ppat.1009711"},{"key":"19","unstructured":"19) World Health Organization: WHO fungal priority pathogens list to guide research, development and public health action. Geneva, 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240060241"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Bosetti D, Neofytos D: Invasive aspergillosis and the impact of azole-resistance. Curr Fungal Infect Rep 17: 77–86, 2023.","DOI":"10.1007\/s12281-023-00459-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hagiwara D, Arai T, Takahashi H, Kusuya Y, Watanabe A, Kamei K: Non-cyp51A azole-resistant Aspergillus fumigatus<\/i> isolates with mutation in HMG-CoA reductase. Emerg Infect Dis 24: 1889–97, 2018.","DOI":"10.3201\/eid2410.180730"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T, Hosogaya N, et al: Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus<\/i>. Antimicrob Agents Chemother 56: 4870–5, 2012.","DOI":"10.1128\/AAC.00514-12"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chowdhary A, Kathuria S, Xu J, Meis JF: Emergence of azole-resistant Aspergillus fumigatus<\/i> strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 9: e1003633, 2013.","DOI":"10.1371\/journal.ppat.1003633"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Lamoth F: Aspergillus fumigatus<\/i>-related species in clinical practice. Front Microbiol 7: 683, 2016.","DOI":"10.3389\/fmicb.2016.00683"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Escribano P, Pel\u00e1ez T, Mu\u00f1oz P, Bouza E, Guinea J: Is azole resistance in Aspergillus fumigatus<\/i> a problem in Spain? Antimicrob Agents Chemother 57: 2815–20, 2013.","DOI":"10.1128\/AAC.02487-12"},{"key":"26","unstructured":"26) Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard - second edition. Wayne, PA, 2008."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Subcommittee on Antifungal Susceptibility Testing of the EECfAST: EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 14: 982–4, 2008.","DOI":"10.1111\/j.1469-0691.2008.02086.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, et al: Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus<\/i> isolates. J Clin Microbiol 49: 1110–2, 2011.","DOI":"10.1128\/JCM.02432-10"},{"key":"29","unstructured":"29) Clinical and Laboratory Standards Institute: Performance standards for antifungal susceptibility testing of filamentous fungi. Wayne, PA: Clinical and Laboratory Standards Institute, 2020."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Arendrup MC, Cuenca-Estrella M, Lass-Fl\u00f6rl C, Hope WW: Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida<\/i> spp. and triazoles against Aspergillus<\/i> spp. Drug Resist Updat 16: 81–95, 2013.","DOI":"10.1016\/j.drup.2014.01.001"},{"key":"31","unstructured":"31) EUCAST. Testing TECoAS: Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures. 2023."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, et al: Molecular identification of Aspergillus<\/i> species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 47: 3138–41, 2009.","DOI":"10.1128\/JCM.01070-09"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Alastruey-Izquierdo A, Mellado E, Pel\u00e1ez T, Pem\u00e1n J, Zapico S, Alvarez M, et al: Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 57: 3380–7, 2013.","DOI":"10.1128\/AAC.00383-13"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL: Aspergillus<\/i> section Fumigati<\/i>: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 52: 1244–51, 2008.","DOI":"10.1128\/AAC.00942-07"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kwizera R, Abdolrasouli A, Garcia-Effron G, Denning DW: Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings. Lancet Infect Dis 24: e782–e93, 2024.","DOI":"10.1016\/S1473-3099(24)00429-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Florensia Dana Carla B, Fachriza A, Thaufik Umar M, Unawekla JE, Anggraini WA, Mir M, et al: Nanostructured lipid carriers-loaded dry powder inhaler for pulmonary delivery of amphotericin B in treatment of allergic bronchopulmonary aspergillosis. Int J Pharm 682: 125926, 2025.","DOI":"10.1016\/j.ijpharm.2025.125926"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Jeong JH, Lee HS, Choi JC, Kang JH, Kim DW, Park CS, et al: Lung-targeted itraconazole delivery using PVA-based nano-in-microparticles for improved treatment of pulmonary aspergillosis. Int J Nanomedicine 20: 4357–80, 2025.","DOI":"10.2147\/IJN.S511099"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Halliday CL, Tay E, Green W, Law D, Lopez R, Faris S, et al: In vitro<\/i> activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023. J Antimicrob Chemother 79: 2611–21, 2024.","DOI":"10.1093\/jac\/dkae267"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kushima H, Ishii H, Kinoshita Y, Fujita M, Watanabe K: Chronic pulmonary aspergillosis with pleuroparenchymal fibroelastosis-like features. Intern Med 58: 1137–40, 2019.","DOI":"10.2169\/internalmedicine.1930-18"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kushima H, Tsunoda T, Matsumoto T, Kinoshita Y, Izumikawa K, Shirasawa S, et al: Effects of Aspergillus fumigatus<\/i> conidia on apoptosis and proliferation in an in vitro<\/i> model of the lung microenvironment. Microorganisms 9: 1435, 2021.","DOI":"10.3390\/microorganisms9071435"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Casadevall A: Global warming could drive the emergence of new fungal pathogens. Nat Microbiol 8: 2217–9, 2023.","DOI":"10.1038\/s41564-023-01512-w"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Wang Z, Shao J: Fungal vaccines and adjuvants: A tool to reveal the interaction between host and fungi. Arch Microbiol 206: 293, 2024.","DOI":"10.1007\/s00203-024-04010-7"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Chechi JL, da Costa FAC, Figueiredo JM, de Souza CM, Valdez AF, Zamith-Miranda D, et al: Vaccine development for pathogenic fungi: Current status and future directions. Expert Rev Vaccines 22: 1136–53, 2023.","DOI":"10.1080\/14760584.2023.2279570"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Slarve M, Holznecht N, Reza H, Gilkes A, Slarve I, Olson J, et al: Recombinant Aspergillus fumigatus<\/i> antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis. Vaccine 40: 4160–8, 2022.","DOI":"10.1016\/j.vaccine.2022.05.057"}],"container-title":["Medical Mycology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/67\/2\/67_117\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:28:39Z","timestamp":1780716519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/67\/2\/67_117\/_article"}},"subtitle":["From the Diagnosis to Future Strategies"],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.26.008","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}